GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (FRA:DBV) » Definitions » Additional Paid-In Capital

DBV Technologies (FRA:DBV) Additional Paid-In Capital : €349.07 Mil(As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is DBV Technologies Additional Paid-In Capital?


DBV Technologies's quarterly additional paid-in capital declined from Sep. 2023 (€352.55 Mil) to Dec. 2023 (€346.14 Mil) but then increased from Dec. 2023 (€346.14 Mil) to Mar. 2024 (€349.07 Mil).

DBV Technologies's annual additional paid-in capital increased from Dec. 2021 (€316.93 Mil) to Dec. 2022 (€432.56 Mil) but then declined from Dec. 2022 (€432.56 Mil) to Dec. 2023 (€346.14 Mil).

DBV Technologies Additional Paid-In Capital Historical Data

The historical data trend for DBV Technologies's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DBV Technologies Additional Paid-In Capital Chart

DBV Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 903.24 946.98 316.93 432.56 346.14

DBV Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 429.50 346.83 352.55 346.14 349.07

DBV Technologies Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

DBV Technologies Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of DBV Technologies's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

DBV Technologies (FRA:DBV) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (FRA:DBV) » Definitions » Additional Paid-In Capital
Comparable Companies
XPAR:NANO XPAR:IPH XPAR:IVA XPAR:AELIS XPAR:MEDCL XPAR:GNFT XPAR:TNG XPAR:ALSEN XPAR:ADOC XPAR:OSE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
DBVT:USA 0QAJ:UK DBV:France DBV:Germany
Address
177-181 avenue Pierre Brossolette, Montrouge, FRA, 92120
Website
http://www.dbvtechnologies.com
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.